Garcia-Marin, Luis M.
Mulcahy, Aoibhe
Byrne, Enda M.
Medland, Sarah E.
Wray, Naomi R.
Chafota, Freddy
Lind, Penelope A.
Martin, Nicholas G.
Hickie, Ian B.
Rentería, Miguel E.
Campos, Adrian I.
Article History
Received: 15 May 2023
Accepted: 13 November 2023
First Online: 24 November 2023
Declarations
:
: This study was approved by the QIMR Berghofer Human and Research Ethics Committee under project number P1218, and data were collected with the support and approval of the Australian Government Department of Human Services (DHS). Research conducted in the present study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: Professor Ian Hickie is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney, Australia. The BMC operates an early-intervention youth services at Camperdown under contract to headspace. Professor Hickie has previously led community-based and pharmaceutical industry-supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) projects focused on the identification and better management of anxiety and depression. He is the Chief Scientific Advisor to, and a 5% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian Government-funded Project Synergy (2017–20) and to lead transformation of mental health services internationally through the use of innovative technologies. Adrian Campos is a current employee of Regeneron pharmaceuticals and may hold stock or stock options.